Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen - LARVOL DELTA

AstraZeneca results: H1 and Q2 2025 (AstraZeneca) - "Total Revenue up 11% to $28,045m, driven by double-digit growth in Oncology and BioPharmaceuticals...The stable Gross Margin (Reported and Core) in H1 2025 was a result of: Positive effects from geographic mix; Negative effects from product mix. The rising contribution of Product Sales with profit sharing arrangements (Lynparza, Enhertu, Tezspire, Koselugo) has a negative impact on Gross Margin because AstraZeneca records Product Sales in certain markets and pays away a share of the gross profits to its collaboration partners."

Commercial • Asthma • Breast Cancer • Chronic Obstructive Pulmonary Disease • Dermatology • Endometrial Cancer • Gastric Cancer • Glioblastoma • Inflammation • Neurofibromatosis • Non Small Cell Lung Cancer • Prostate Cancer

REAL-WORLD STUDY: IMPACT OF BMI IN TEZEPELUMAB TREATED SEVERE ASTHMA PATIENTS (CHEST 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Asthma • Immunology • Respiratory Diseases

IMPACT OF PRIOR BIOLOGIC CLASS ON REAL-WORLD TEZEPELUMAB OUTCOMES IN SEVERE ASTHMA (CHEST 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Asthma • Immunology • Respiratory Diseases

IMPACT OF AGE OF ASTHMA ONSET ON TEZEPELUMAB OUTCOMES: A REAL-WORLD EXPERIENCE (CHEST 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Asthma • Immunology • Respiratory Diseases

TEZEPELUMAB EFFECTIVENESS IN US PATIENTS WITH SEVERE ASTHMA AND COMORBID CHRONIC OBSTRUCTIVE PULMONARY DISEASE OR SIGNIFICANT SMOKING HISTORY: RESULTS FROM THE PASSAGE STUDY (CHEST 2025) - No abstract available

Clinical • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

SUCCESSFUL TREATMENT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSwNP) WITH TEZEPELUMAB: A CASE REPORT (CHEST 2025) - No abstract available

Case report • Clinical • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

COMPARATIVE OUTCOMES OF DUPILUMAB AND TEZEPELUMAB IN ASTHMA MANAGEMENT: A REAL-WORLD ANALYSIS (CHEST 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Asthma • Immunology • Respiratory Diseases

AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS (Amgen Press Release) - "TEZSPIRE (tezepelumab-ekko) sales increased 46% year-over-year to $342 million in the second quarter, driven by volume growth. Otezla (apremilast) sales increased 14% year-over-year to $618 million in the second quarter, driven by 12% favorable changes to estimated sales deductions and 4% volume growth. Enbrel (etanercept) sales decreased 34% year-over-year to $604 million in the second quarter, driven by 20% unfavorable changes to estimated sales deductions and 19% lower net selling price resulting from increased 340B Program mix and the impact of the U.S. Medicare Part D redesign, partially offset by 3% volume growth."

Sales • Asthma • Dermatology • Immunology • Psoriatic Arthritis • Rheumatoid Arthritis

Therapeutic application of cytokine antagonists in chronic obstructive pulmonary disease (PubMed, Zhonghua Jie He He Hu Xi Za Zhi) - "Biologics targeting type 2 inflammation, such as Tezepelumab (targeting thymic stromal lymphopoietin, TSLP), Itepekimab and Astegolimab (targeting IL-33), and Dupilumab (targeting IL-4/IL-13), have demonstrated potential in clinical trials to improve outcomes and enhance the quality of life for COPD patients. This article systematically outlines the molecular mechanisms of type 2 inflammation in COPD and the progress in targeted therapies. It emphasizes that the clinical translation of biologics must be guided by precision medicine, integrating mechanistic research with real-world evidence to advance COPD treatment towards "individualized intervention." Future research needs to further elucidate the interactions between type 2 and non-type 2 inflammatory phenotypes and to explore combination therapeutic strategies, in order to provide more comprehensive solutions for the prevention and management of COPD."

Journal • Review • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL13 • IL33 • IL4 • IL5 • TSLP

Tezspire: “TEZSPIRE sales increased 46% YoY, driven by volume growth” (Amgen) - Q2 2025 Results

Commercial • Asthma • Immunology • Respiratory Diseases

The use of biologic therapies in pediatric severe asthma. (PubMed, Expert Rev Respir Med) - "This review provides an overview of the current evidence on biologic therapies approved for pediatric severe asthma, including omalizumab, mepolizumab, benralizumab, and dupilumab...We also examine emerging biologic agents targeting upstream pathways, such as tezepelumab and anti-IL-33 therapies, and explore the concept of asthma remission and its implications for long-term disease trajectories...However, challenges persist in optimizing patient selection, enhancing access, and comprehending long-term outcomes. Future research should focus on early intervention strategies, cost-effectiveness analyses, and the potential for disease-modifying effects in children."

Journal • Review • Asthma • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases • IL33

"TSLP and Nasal Epithelium: A Missing Link in Tezepelumab's Mechanism"-Reply. (PubMed, Int Forum Allergy Rhinol) - No abstract available

Journal • TSLP

"Clinical and Biological Remission With Tezepelumab: The Real-World Response in Severe Uncontrolled Asthma". (PubMed, Allergy) - No abstract available

Journal • Real-world evidence • Allergy • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Analysis of adverse reaction characteristics of four biologics for the treatment of chronic sinusitis with nasal polyps: A descriptive analysis from WHO-VigiAccess. (PubMed, Am J Otolaryngol) - "This study delineates agent-specific ADR profiles tied to mechanistic targets, advocating for tailored monitoring strategies. Findings underscore the imperative for risk-stratified biologic selection in CRSwNP management, supported by ongoing pharmacovigilance and mechanistic investigations."

Journal • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Musculoskeletal Diseases • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

EVOLVE Study: The Real-life Clinical Practice With Tezepelumab in Greece (clinicaltrials.gov) - P=N/A | N=150 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Biologic Therapy in Severe Asthma: A Phenotype-Driven and Targeted Approach. (PubMed, J Clin Med) - "Furthermore, we present a practical decision-making platform, including a clinical table matching phenotypes with biologic agents, such as omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab. By integrating biomarker analysis with clinical assessment, based on current guidelines and our extensive real-life experience, we aim to offer a logical framework to help clinicians select the most suitable biologic treatment for patients with uncontrolled severe asthma. Future research should focus on identifying novel biomarkers, refining patient stratification, and evaluating long-term outcomes to further advance precision medicine in the management of severe asthma."

Journal • Review • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • POSTN

Switching patients with severe eosinophilic asthma from Tezepelumab to Benralizumab (ERS 2025) - No abstract available

Clinical • Asthma • Immunology • Respiratory Diseases

FAERS-Based Disproportionality Analysis of Diabetes Mellitus in Patients Treated with Biologics for Asthma and Related Conditions. (PubMed, Pulm Pharmacol Ther) - "This FAERS-based analysis identified a potential pharmacovigilance signal for DM associated with several biologics used to treat asthma and related conditions, most notably omalizumab and benralizumab. Similar patterns were observed for metabolic AEs, which reinforces the need for post-marketing studies and clinical awareness in patients with or at risk for metabolic disorders."

Journal • Asthma • Diabetes • Immunology • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases

Choosing biologic therapy in children with severe asthma. (PubMed, Paediatr Respir Rev) - "Omalizumab, a monoclonal antibody targeting IgE, was the first biologic therapy approved in 2003 for treating severe, allergen-driven, therapy-resistant asthma. Since then, many new biologics have been approved for use in children, targeting specific pathways, including anti-interleukin (IL)-5 (mepolizumab), IL-5 receptor (benralizumab), IL-4/IL-13 receptor (dupilumab), and thymic stromal lymphopoietin (TSLP) (tezepelumab)...These include accurately identifying the endotype/phenotype of asthmatic inflammation and determining response criteria. Here, we summarise findings from phase 3 trials, discuss practical considerations for individual patients, and propose an algorithm for initiating biologics in children and adolescents with severe asthma."

Journal • Review • Asthma • Eosinophilia • Immunology • Inflammation • Pediatrics • Pulmonary Disease • Respiratory Diseases • IL13 • IL4 • IL5 • TSLP

Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis. (PubMed, J Allergy Clin Immunol) - "Among individuals with chronic urticaria refractory to antihistamines, standard-dose omalizumab and remibrutinib are among the most effective drugs across multiple patient-important outcomes with a favorable safety profile across the studied duration. Cyclosporine may be effective but may be among the most harmful. Dupilumab improves itch and wheals, but it is uncertain whether it improves angioedema or quality of life. Lower doses of omalizumab are of intermediate effectiveness and favorable safety. The net benefit of conventional immunosuppressants is uncertain."

Journal • Retrospective data • Cardiovascular • Dermatology • Immunology • Urticaria

Clinical characteristics associated with frequent asthma exacerbations whilst on treatment with tezepelumab (ERS 2025) - No abstract available

Clinical • Asthma • Immunology • Respiratory Diseases

Efficacy of tezepelumab in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps and comorbid NSAID-exacerbated respiratory disease (WAYPOINT) (ERS 2025) - No abstract available

Clinical • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Tezepelumab in Uncontrolled Severe Asthma: A 3-Month Study on Small Airway Function and Symptom Control (ERS 2025) - No abstract available

Asthma • Immunology • Respiratory Diseases

Real-world Impact of Tezepelumab in Severe Asthma: insights from the ADVANCAT Study (Advancing Severe Asthma Care with Tezepelumab in Catalonia) (ERS 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Asthma • Immunology • Respiratory Diseases

Characteristics of Severe Asthmatics commencing Tezepelumab from the South West Asthma Network (SWAN) (UK) (ERS 2025) - No abstract available

Asthma • Immunology • Respiratory Diseases